| 1 |
30237210 | A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. | 2019 Apr |
3 |
| 2 |
31262905 | Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp. | 2019 Jul |
1 |
| 3 |
29175983 | Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET. | 2018 Jun |
2 |
| 4 |
29311482 | Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. | 2018 |
2 |
| 5 |
29420339 | Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer. | 2018 Apr |
3 |
| 6 |
30127938 | Preliminary evaluation of the potential role of β-elemene in reversing erlotinib-resistant human NSCLC A549/ER cells. | 2018 Sep |
2 |
| 7 |
27493269 | Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates. | 2017 Jan |
4 |
| 8 |
26359257 | Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib. | 2015 Dec |
3 |
| 9 |
23277288 | PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors. | 2013 Mar 12 |
1 |
| 10 |
23532985 | Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. | 2013 Jul |
1 |
| 11 |
22462752 | Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. | 2012 Apr |
3 |
| 12 |
23095522 | Erlotinib antagonizes ABC transporters in acute myeloid leukemia. | 2012 Nov 1 |
1 |
| 13 |
21653689 | Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. | 2011 Jul 15 |
1 |
| 14 |
19720054 | Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. | 2010 Jan 15 |
3 |
| 15 |
18006847 | Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. | 2007 Nov 15 |
9 |